

Markus Schwarz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1866492/publications.pdf>

Version: 2024-02-01

38
papers

1,958
citations

304743

22
h-index

302126

39
g-index

43
all docs

43
docs citations

43
times ranked

2874
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D levels in children and adolescents with chronic tic disorders: a multicentre study. <i>European Child and Adolescent Psychiatry</i> , 2022, 31, 1-12.	4.7	12
2	Association of Group A <i>Streptococcus</i> Exposure and Exacerbations of Chronic Tic Disorders. <i>Neurology</i> , 2021, 96, e1680-e1693.	1.1	30
3	Activation and deactivation steps in the tryptophan breakdown pathway in major depressive disorder: A link to the monocyte inflammatory state of patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110226.	4.8	12
4	Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110391.	4.8	43
5	<i>Mycoplasma pneumoniae</i> IgG positivity is associated with tic severity in chronic tic disorders. <i>Brain, Behavior, and Immunity</i> , 2021, 99, 281-288.	4.1	6
6	Actovegin® reduces PMA-induced inflammation on human cells. <i>European Journal of Applied Physiology</i> , 2020, 120, 1671-1680.	2.5	9
7	Differences in Kynurenine Metabolism During Depressive, Manic, and Euthymic Phases of Bipolar Affective Disorder. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1344-1352.	2.1	8
8	Effects of inflammation modulation on tryptophan and kynurenine pathway regulation in treatment resistant bipolar depression. <i>Neurology Psychiatry and Brain Research</i> , 2019, 33, 65-72.	2.0	6
9	S97. Celecoxib Augmentation of Escitalopram in Treatment-Resistant Bipolar Depression and the Effects on Quinolinic Acid in the Kynurenine Pathway. <i>Biological Psychiatry</i> , 2019, 85, S334-S335.	1.3	0
10	Celecoxib augmentation of escitalopram in treatment-resistant bipolar depression and the effects on Quinolinic Acid. <i>Neurology Psychiatry and Brain Research</i> , 2019, 32, 22-29.	2.0	13
11	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 162-174.	2.6	103
12	Kynurenine pathway and white matter microstructure in bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 157-168.	3.2	34
13	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 330-356.	2.6	33
14	Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder. <i>PLoS ONE</i> , 2017, 12, e0172699.	2.5	63
15	Soluble Intracellular Adhesion Molecule-1 in Patients with Unipolar or Bipolar Affective Disorders: Results from a Pilot Trial. <i>Neuropsychobiology</i> , 2016, 74, 8-14.	1.9	12
16	Oxytocin course over pregnancy and postpartum period and the association with postpartum depressive symptoms. <i>Archives of Women's Mental Health</i> , 2016, 19, 571-579.	2.6	54
17	Is <i>T</i> helper type 2 shift schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 228-236.	1.8	28
18	Methylphenidate Effects on Neural Activity During Response Inhibition in Healthy Humans. <i>Cerebral Cortex</i> , 2013, 23, 1179-1189.	2.9	55

#	ARTICLE	IF	CITATIONS
19	Intracellular monocytic cytokine levels in schizophrenia show an alteration of IL-6. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 393-401.	3.2	22
20	The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. <i>Journal of Psychopharmacology</i> , 2012, 26, 33-41.	4.0	110
21	Monocytic HLA DR antigens in schizophrenic patients. <i>Neuroscience Research</i> , 2012, 72, 87-93.	1.9	13
22	Tryptophan Depletion and Emotional Processing in Healthy Volunteers at High Risk for Depression. <i>Biological Psychiatry</i> , 2011, 69, 804-807.	1.3	36
23	In vivo type II T-helper cells shift in schizophrenia compared to sex- and age-matched healthy controls. <i>European Journal of Psychiatry</i> , 2011, 25, 192-204.	1.3	4
24	Serum concentrations of paliperidone versus risperidone and clinical effects. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 797-803.	1.9	43
25	Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. <i>Journal of Neuroimmunology</i> , 2010, 221, 62-67.	2.3	16
26	Effects of mirtazapine on dehydroepiandrosterone-sulfate and cortisol plasma concentrations in depressed patients. <i>Journal of Psychiatric Research</i> , 2009, 43, 538-545.	3.1	23
27	COX-2 Inhibition in Schizophrenia and Major Depression. <i>Current Pharmaceutical Design</i> , 2008, 14, 1452-1465.	1.9	94
28	T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. <i>Psychiatry Research</i> , 2007, 152, 173-180.	3.3	64
29	Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients. <i>Psychoneuroendocrinology</i> , 2007, 32, 669-680.	2.7	14
30	Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. <i>Journal of Neuroimmunology</i> , 2007, 189, 169-174.	2.3	15
31	Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. <i>Neurotoxicity Research</i> , 2006, 10, 131-148.	2.7	205
32	Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls. <i>Archives of General Psychiatry</i> , 2006, 63, 978.	12.3	140
33	The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 334-340.	3.2	4
34	Neural and Behavioral Responses to Tryptophan Depletion in Unmedicated Patients With Remitted Major Depressive Disorder and Controls. <i>Archives of General Psychiatry</i> , 2004, 61, 765.	12.3	245
35	Interferon-alpha, cytokines and possible implications for mood disorders. <i>Bipolar Disorders</i> , 2002, 4, 111-113.	1.9	13
36	Vigabatrin Decreases Cholecystinin-Tetrapeptide (CCK-4) Induced Panic in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2001, 25, 699-703.	5.4	59

#	ARTICLE	IF	CITATIONS
37	The T102C Polymorphism of the 5-HT _{2A} -Receptor Gene in Fibromyalgia. <i>Neurobiology of Disease</i> , 1999, 6, 433-439.	4.4	179
38	Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1997, 247, 308-313.	3.2	124